<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171687</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_113</org_study_id>
    <nct_id>NCT04171687</nct_id>
  </id_info>
  <brief_title>Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Explore the Drug Interaction of Tegoprazan or RAPA113 and Clopidogrel After Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the influence of tegoprazan or RAPA113 on the
      pharmacodynamics/Pharmacokinetics of following co-administration of tegoprazan or RAPA113 and
      clopidogrel in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Criteria:

        -  Primary outcome Pharmacodynamic assessments using P2Y12 assay

        -  Secondary outcome Pharmacokinetics assessments on Cmax,ss, AUCτ,ss, tmax,ss, Cmin,ss ,
           CLss/F of Clopidogrel

        -  Safety assessments with adverse event monitoring including subjective/objective
           symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Actual">April 9, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in P2Y12 Reaction Unit (PRU) from baseline</measure>
    <time_frame>Pre-dose(0h) on days 1, 3, 5, 7 and 8 in each period</time_frame>
    <description>Pharmacodynamics blood sampling to measure PRU using VerifyNow® system</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet and Tegoprazan 50mg tablet once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg + RAPA113</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of clopidogrel 75 mg tablet and RAPA113 tablet once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>Clopidogrel 75 mg tablet</description>
    <arm_group_label>Clopidogrel 75 mg</arm_group_label>
    <arm_group_label>Clopidogrel 75 mg + RAPA113</arm_group_label>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Clopidogrel 75 mg + Tegoprazan 50 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAPA113</intervention_name>
    <description>RAPA113 tablet</description>
    <arm_group_label>Clopidogrel 75 mg + RAPA113</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written informed
             consent

          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.5 kg/m2 and
             ≤ 27.0 kg/m2 at the time of screening

          -  Helicobacter pylori negative

          -  Voluntarily decided to participate in the study and provided written informed consent
             before any screening procedure

        Exclusion Criteria:

          -  Has a history of or currently has clinically significant liver, kidney, nervous
             system, immune system, respiratory system, endocrine system, blood, tumor,
             cardiovascular system or psychiatric disease

          -  Has a history of gastrointestinal diseases (such as Crohn's disease, ulcer, etc.) or
             surgery (except for simple appendectomy or hernia) that can affect the absorption of
             drugs

          -  Has a genetic problems such as galactose intolerance, Lapp lactase deficiency, or
             glucose-galactose malabsorption

          -  Has a clinically significant history of hemorrhage (e.g. Gastric ulcers, intracranial
             bleeding, haemophilia, gastrointestinal bleeding, urinary tract bleeding, vitreous
             hemorrhage, etc.)

          -  P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range
             by 10% at screening

          -  Considered ineligible to participate in the study based on screening test(by asking
             condition, vital sign, 12-lead ECG, physical exam, laboratory test etc.) results :

               1. Platelet, PT and aPTT levels outside the upper/lower limit of normal range by 10%

               2. AST (GOT), and ALT (GPT) levels greater than 1.25x of the upper limit of normal
                  range

               3. Blood total bilirubin levels greater than 1.5x of the upper limit of normal range

               4. Hemoglobin levels less than 12.0 g/dL

               5. eGFR (estimated Glomerular Filtration Rate) using MDRD (Modification of Diet in
                  Renal Disaster) &lt; 60 mL/min/1.73 m2

                  : eGFR (estimated glomerular filtration rate) (mL/min/1.73m2) = 175 x [serum
                  creatinine (mg/dL)]-1.154 x [age]-0.203

               6. positive as a result of serum examination (B-type hepatitis test, hepatitis C
                  test, human immunodeficiency virus test, syphilis test)

               7. Systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg, diastolic blood pressure &lt; 50
                  mmHg or &gt; 100 mmHg, or pulse rate &lt; 45 beats/minute or &gt; 100 beats/minute when
                  vital signs are measured in sitting position after resting for at least 5 minutes
                  during screening
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital, Dept of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

